Fate Therapeutics, Inc. (FATE) Analyst Forecast

NASDAQ Currency in USD Disclaimer

Stock Price

$2.28

$0.26

(12.84%)

Day's range

$2.23

$3.5

Consensus Rating

Hold

Based on 28 Analyst Ratings
Consensus Price Target

$39.67

1639.91% Upside

Recent Analyst Forecasts and Stock Ratings

Date	Brokerage Firm	Analyst Name	Price Target	Price when Posted	Upside/Downside on Report Date	Details
11/13/2024	BMO Capital	Etzer Darout	$5.00	$3.37	48.37%
08/14/2024	Stifel Nicolaus	Benjamin Burnett	$5.00	$3.27	52.91%
06/16/2024	Piper Sandler	Edward Tenthoff	$6.00	$3.61	66.44%
05/16/2024	H.C. Wainwright	Debjit Chattopadhyay	$5.00	$4.24	17.92%
05/10/2024	Piper Sandler	Edward Tenthoff	$4.00	$3.88	3.09%
05/10/2024	BMO Capital	Etzer Darout	$6.00	$3.87	55.24%
05/10/2024	Canaccord Genuity	Bill Maughan	$9.00	$3.90	130.77%
01/05/2023	Truist Financial	Robyn Karnauskas	$7.00	$11.00	-36.36%
12/14/2022	Goldman Sachs	Andrea Tan	$10.00	$15.37	-34.94%
12/12/2021	Oppenheimer	Matthew Biegler	$135.00	$48.98	175.62%
11/07/2021	Citigroup	Yigal Nochomovitz	$87.00	$60.79	43.12%
11/04/2021	Roth Capital	Anthony Butler	$60.00	$61.42	-2.31%
10/24/2021	Jefferies	Michael Yee	$145.00	$58.16	149.31%
08/19/2021	Piper Sandler	Edward Tenthoff	$113.00	$67.01	68.63%

Fate Therapeutics, Inc. Frequently Asked Questions

What analysts cover Fate Therapeutics, Inc.?

Fate Therapeutics, Inc. has been rated by research analysts at BMO Capital, Stifel Nicolaus, Piper Sandler, H.C. Wainwright, Canaccord Genuity, Goldman Sachs in the past 90 days.

×

New Alert

Select an alert type

Sentiment Spike

Send email alert if news sentiment changes significantly

Mentions Spike

Send email alert if has a surge in mentions

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In

Email Address

or

download app using google store

Continue with Google

download app using apple

Continue with Apple

By signing in you agree to our terms of service and privacy policy.

Don't have an account? Sign up

Email Verification

An email with a verification code has been sent to your email address.

Verification Code / OTP

Didn't receive the code?

Welcome to Stocks.News!

or

google app download

Continue with Google

ios app download

Continue with Apple

By signing up you agree to our terms of service and privacy policy.

Already have an account? Log in

Create Your Account

Name

Email Address

By signing up you agree to our terms of service and privacy policy.

Already have an account? Log in

Email Verification

An email with a verification code has been sent to your email address.

Verification Code / OTP

Didn't receive the code?